A 12-month update of BOLT, a phase 2, randomized, double-blind study of sonidegib (LDE225) in patients with locally advanced or metastatic basal cell carcinoma - 09/05/15
Michael Migden, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, United States; Ralf Gutzmer, MD, Medizinische Hochschule Hannover, Hannover, Germany; Alexander Guminski, MBBS, PhD, Royal North Shore Hospital, St Leonards, Australia; Tingting Yi, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Sven Gogov, MD, Novartis Pharma AG, Basel, Switzerland; John Lear, MD, Manchester Royal Infirmary, Manchester, United Kingdom; Reinhard Dummer, MD, Universitätsspital Zürich—Skin Cancer Center University Hospital, Zürich, Switzerland
Le texte complet de cet article est disponible en PDF. Medical editorial assistance was provided by Articulate Science, LLC. Financial support for editorial assistance was provided by Novartis Pharmaceuticals Corporation. This study was funded by Novartis Pharmaceuticals Corporation. |
Vol 72 - N° 5S1
P. AB178 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?